Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Take-home naloxone kits preventing overdose deaths

Laura Eggertson
CMAJ January 07, 2014 186 (1) 17; DOI: https://doi.org/10.1503/cmaj.109-4663
Laura Eggertson
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The first time Laura Shaver injected naloxone into a fellow drug user to save his life, she was crouched in a tent in the mountains outside Nelson, British Columbia. Friends in a nearby tent had awoken her with news that one of their companions had overdosed on methadone. Grabbing her flashlight, a bottle of naloxone and a clean syringe, Shaver raced to help.

The man had been smoking cocaine and drinking alcohol and methadone. His lips were blue and he wasn’t breathing. Although she has no formal medical education, Shaver was fresh from training by the BC Centre for Disease Control on how to intervene in opioid drug overdoses. Since 2012, the BC Take Home Naloxone program has trained more than 575 opioid drug users, family and friends and service providers and distributed more than 440 kits to prevent overdose deaths.

Holding the flashlight under her chin, Shaver jabbed the syringe into the man’s leg. She began breathing into his mouth and pumping his chest. Within seconds, he came around, but then lapsed into unconsciousness again. Shaver and another friend with medical training took turns readministering the naloxone and performing cardiopulmonary resuscitation until an ambulance finally made it to their remote location.

Once in hospital, after further administrations of naloxone, the man survived. For Shaver, who is on the board of the Vancouver Area Network of Drug Users (VANDU), the intervention was the first of 10 times she has administered naloxone. The medication, which works in two to five minutes, forces opioids such as heroin, methadone, oxycodone and fentanyl off the receptors in the brain and restores breathing. The drug works for 30–90 minutes, so overdoses may continue if people don’t get additional medical treatment.

BC’s Take Home Naloxone program is one of just four in Canada, the first of which began in Edmonton, Alberta, in 2005. In 2011, Toronto Public Health in Ontario launched its POINT (Preventing Overdose in Toronto) program. POINT has so far distributed 900 kits and collected reports of 115 people administering naloxone successfully, says Chantel Marshall, a health promotion consultant with Toronto Public Health.

Figure1

The BC Centre for Disease Control’s harm reduction office has documented 45 overdose reversals since they began distributing naloxone kits

Image courtesy of Harm Reduction Program, BC Centre for Disease Control

Ottawa Public Health in Ontario created the Peer Overdose Prevention Program (POPP) that launched the same day as BC began its province-wide program, on Aug. 31, 2012. All the programs train active users of opioids (prescription or nonprescription) and their family and friends. Program administrators can provide naloxone only to users, via a prescription, but they train anyone who might witness an overdose on how to use the drug’s accompanying kit.

“Eighty-five percent of overdoses happen in the company of others, so when we are training people in the use of naloxone, it’s not just for them, it’s for other people as well,” says Dr. Jane Buxton, head of the BC Centre for Disease Control’s harm reduction office.

The program is saving lives, says Buxton, who has documented 45 overdose reversals since they began distributing naloxone kits. She views the program as a harm reduction tool and a cost-effective approach to opioid safety. In 2009, there were 70 deaths in BC involving prescription opioid medication, and 259 people died in 2012 from using illicit drugs. Take Home Naloxone has now distributed kits to 30 clinics, pharmacies and doctors’ offices across BC, as well as to Vancouver’s Insite supervised injection site. “Not only does it not increase the amount of drugs used, but people who have been trained are more safety conscious and are at less risk of an overdose,” says Buxton.

Despite the evidence that distributing the kits work, naloxone is not available on all provincial formularies. In Ontario, it is not listed on the formulary or available through the province’s Exceptional Access Program. That means organizations that want to distribute naloxone kits have to buy the medication from provinces or manufacturers and pass it out themselves, says POINT’s Marshall. She describes that as a barrier and would like to see naloxone kits available for every doctor to dispense.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (1)
CMAJ
Vol. 186, Issue 1
7 Jan 2014
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Take-home naloxone kits preventing overdose deaths
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Take-home naloxone kits preventing overdose deaths
Laura Eggertson
CMAJ Jan 2014, 186 (1) 17; DOI: 10.1503/cmaj.109-4663

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Take-home naloxone kits preventing overdose deaths
Laura Eggertson
CMAJ Jan 2014, 186 (1) 17; DOI: 10.1503/cmaj.109-4663
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program
  • Scopus (4)
  • Google Scholar

More in this TOC Section

  • Canada’s health system is among the least green
  • Some provinces still delay access to health records via patient portals
  • Nausea-inducing illness caused by cannabis still underdiagnosed
Show more News

Similar Articles

Collections

  • Topics
    • Pharmacology & toxicology
    • Addiction medicine

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire